QA: Neubase Therapeutics Inc in us_pharma/2021

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001173281_2022_Neubase_Therapeutics_Inc.pdf

Logs

warning The stock price does not exist industry.us_generic {}
warning Missing logo subcommand.report {}

Graph

Absolute values for 0001173281, Neubase Therapeutics Inc

  xvar xval
0 AssetsCurrent 54,928,634
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 2,463,882
3 remainder_Assets 6,775,077
4 LiabilitiesCurrent 4,194,224
5 LiabilitiesNoncurrent 5,794,096
6 remainder_Liabilities 109,500
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 12,202,217
9 ResearchAndDevelopmentExpense 11,475,201
10 remainder_Expenses 2,888,029
11 remainder_Revenues 0
12 remainder_NetIncome 1,156,146
13 remainder_ComprehensiveNetIncome 0
  yvar yval
0 Assets 64,167,593
1 Liabilities 10,097,820
2 Expenses 26,565,447
3 Revenues 0
4 StockholdersEquity 54,069,773
5 NetIncome -25,409,301
6 ComprehensiveNetIncome -25,409,301
7 BaseVar 50,993,503
8 EconomicCapitalRatiobeforeLimitedLiability 2.49
9 EconomicCapitalRatio 3.35

Edgar->Model Mapping

Feature Distribution

Change over Time